127 related articles for article (PubMed ID: 14608530)
1. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia.
Iravani S; Zhang HQ; Yuan ZQ; Cheng JQ; Karl RC; Jove R; Coppola D
Hum Pathol; 2003 Oct; 34(10):975-82. PubMed ID: 14608530
[TBL] [Abstract][Full Text] [Related]
2. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
3. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
5. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
[TBL] [Abstract][Full Text] [Related]
6. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.
van der Woude CJ; Jansen PL; Tiebosch AT; Beuving A; Homan M; Kleibeuker JH; Moshage H
Hum Pathol; 2002 Jul; 33(7):686-92. PubMed ID: 12196918
[TBL] [Abstract][Full Text] [Related]
7. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
8. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
10. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma.
Walch A; Specht K; Braselmann H; Stein H; Siewert JR; Hopt U; Höfler H; Werner M
Int J Cancer; 2004 Dec; 112(5):747-53. PubMed ID: 15386389
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus.
Rioux-Leclercq N; Turlin B; Sutherland F; Heresbach N; Launois B; Campion JP; Ramee MP
Oncol Rep; 1999; 6(4):877-82. PubMed ID: 10373674
[TBL] [Abstract][Full Text] [Related]
13. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.
Soslow RA; Ying L; Altorki NK
J Thorac Cardiovasc Surg; 1997 Nov; 114(5):838-43. PubMed ID: 9375615
[TBL] [Abstract][Full Text] [Related]
14. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
15. bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence.
Goldblum JR; Rice TW
Mod Pathol; 1995 Oct; 8(8):866-9. PubMed ID: 8552577
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
17. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
[TBL] [Abstract][Full Text] [Related]
18. Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus.
Jiang K; Neill K; Cowden D; Klapman J; Eschrich S; Pimiento J; Malafa MP; Coppola D
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):552-556. PubMed ID: 27941559
[TBL] [Abstract][Full Text] [Related]
19. Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Soslow RA; Petersen CG; Remotti H; Altorki N
Dis Esophagus; 2001; 14(1):23-7. PubMed ID: 11422301
[TBL] [Abstract][Full Text] [Related]
20. Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior.
Helminen O; Huhta H; Leppänen J; Kauppila JH; Takala H; Lehenkari PP; Saarnio J; Karttunen TJ
Virchows Arch; 2016 Oct; 469(4):465-70. PubMed ID: 27392931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
